Zenas BioPharma Investors Encouraged to Contact Cohen Milstein to Lead ZBIO IPO Stock Drop Securities Class Action

Core Viewpoint - Retail investors in Zenas BioPharma, Inc. may have the opportunity to lead a securities class action lawsuit due to alleged misrepresentation of the company's financial position during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the District of Massachusetts, accusing Zenas BioPharma of misrepresenting its financial status in IPO registration materials [4]. - Zenas BioPharma claimed it had sufficient funds to operate for 24 months, but later disclosed a funding runway of only 12 months in its third-quarter financials [4]. - Since the IPO, Zenas BioPharma's stock price has decreased by nearly 49%, dropping from $17 to$8.72 as of April 15, 2025 [4]. Group 2: Lead Plaintiff Information - A lead plaintiff plays an active role in the litigation and represents the interests of all class members, typically being the investor or group with the largest financial interest [5]. - Filing a motion to be appointed as lead plaintiff is not necessary to share in any recovery, but it allows for a voice in the litigation process [6]. Group 3: Law Firm Background - Cohen Milstein is recognized as a leading plaintiff-side law firm specializing in securities litigation and investor protection, having recovered billions for shareholders [7]. - The firm has received accolades from industry publications, ranking its work and attorneys among the best in the nation [7].